Manufacturing

Articles

The acquisition will allow Charles River to expand its cell and gene therapy development, testing, and manufacturing capabilities, while adding to its existing portfolio of non-clinical capabilities.

Charles River to Acquire Cognate BioServices for $875 Million

The foundation will provide funding support for the discovery and development of a single-administration, in-vivo gene therapy to cure sickle cell disease, a hereditary blood disease.

Novartis and the Bill & Melinda Gates Foundation Team Up to Develop Gene Therapy for Sickle Cell Disease

Catalent will offer materials from its gene therapy facilities in Maryland to support IND-enabling studies and a Phase I/II clinical trial of the product.

Catalent and Decibel Team Up to Develop Gene Therapy for Congenital Hearing Loss

Agnes Shanley is senior editor of Pharmaceutical Technology.

From scale-up and tech transfer to analytical method development and quality testing, alliances between innovators and contract partners, and between CDMOs and technology vendors, are taking more therapies from lab to patient.



Collaboration Takes Cell and Gene Therapies Closer  to Their Full Potential

Evozyne’s evolution-based protein design technology will be used to research and develop proteins that could be used in the next generation of gene therapies.

Takeda and Evozyne Enter into Gene Therapy Collaboration 

Through the acquisition, Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets.

Eli Lilly Completes $1.5 Billion Acquisition of Prevail Therapeutics

Paul S. Larson, MD, paul.larson@ucsf.edu, is professor and vice-chair of Neurological Surgery at the University of California San Francisco, chief of Neurosurgery at the San Francisco Veterans Affairs Medical Center, and surgical director of the Parkinson’s Disease Research, Education and Clinical Center.

Leveraging real-time MRI guidance for intracranial gene therapy administration potentially improves efficacy and outcomes.

iMRI-Guided Gene Therapy and Drug Delivery for CNS Disorders 

The acquisition significantly expands Precision Medicine Group’s cell and gene therapy expertise.

Precision Medicine Group Acquires Project Farma

The collaboration will utilize ViGeneron’s novel engineered AAV capsids, vgAAV, to transduce retinal cells with intravitreal injections for an undisclosed target.

Biogen and ViGeneron Collaborate on Inherited Eye Disease Gene Therapy

Through the acquisition, Eli Lilly will have access to Prevail’s portfolio of clinical-stage and preclinical neuroscience assets. 

Manufacturing, Gene Therapies